Holen Sie sich die Stockscreener-App
143.29
1.40%
1.98
Vorhandelsmarkt:
142.60
-0.69
-0.48%
Schlusskurs vom Vortag:
$141.31
Offen:
$141.62
24-Stunden-Volumen:
1.24M
Relative Volume:
1.03
Marktkapitalisierung:
$14.57B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$668.60M
KGV:
22.03
EPS:
6.5044
Netto-Cashflow:
$831.30M
1W Leistung:
+5.59%
1M Leistung:
+2.72%
6M Leistung:
+10.06%
1J Leistung:
-0.26%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$135.00
$143.83
52-Wochen-Spanne:
$122.14
$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
143.29 | 14.57B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
20.36 | 65.04B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.21 | 46.90B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.37 | 45.60B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.00 | 33.88B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
584.79 | 25.08B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-06 | Fortgesetzt | Guggenheim | Buy |
| 2026-06-02 | Fortgesetzt | Goldman | Buy |
| 2026-05-22 | Eingeleitet | Bernstein | Outperform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Underv - GuruFocus
Neurocrine Biosciences starts Alzheimer's Phase 2 trial - Mugglehead Investment Magazine
Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease - Yahoo Finance
Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment - Pluang
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease - TradingView
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease - PR Newswire
Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings - Yahoo Finance
Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks? - Simply Wall Street
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia - PR Newswire
Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target - TradingView
RBC keeps USD 187.00 target for Neurocrine Biosciences stock - ad-hoc-news.de
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) - Stock Titan
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Non-operating income (total) of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook - Investing.com
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com - Investing.com India
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term - Zacks Investment Research
This Biopharma Stock Offers Compelling Upside After a Pullback - Barron's
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued - GuruFocus
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Singapore
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says - Yahoo Finance
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – FWB:NB3 - TradingView
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term - Zacks Investment Research
BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $150 - Moomoo
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Porterville Recorder
Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Yahoo Finance
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Arizona Daily Star
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. - Stock Titan
Neurocrine Biosciences (NBIX) After New VYKAT XR Data Why The Undervalued Narrative Persists - Simply Wall Street
Neurocrine Biosciences stock fell 1.4 percent before research event - AD HOC NEWS
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock - ChartMill
Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high - AD HOC NEWS
Neurocrine Biosciences Shares Jump on Fresh Long-term CRENESSITY Data Catalyst - Moomoo
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board - Endpoints News
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Australia
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurocrine Biosciences Inc-Aktie (NBIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DAVID WARREN BOYER | Officer |
Sep 14 '26 |
Proposed Sale |
156.22 |
4,714 |
736,421 |
0 |
| MATTHEW C ABERNETHY | Officer |
Sep 14 '26 |
Proposed Sale |
156.22 |
2,311 |
361,024 |
0 |
| ABERNETHY MATT | Chief Financial Officer |
Sep 14 '26 |
Sale |
157.20 |
2,311 |
363,285 |
42,808 |
| ERIC BENEVICH | Officer |
Sep 09 '26 |
Proposed Sale |
155.13 |
2,154 |
334,150 |
0 |
| BENEVICH ERIC | Chief Commercial Officer |
Sep 09 '26 |
Sale |
154.61 |
2,154 |
333,030 |
64,408 |
| BENEVICH ERIC | Chief Commercial Officer |
Sep 09 '26 |
Option Exercise |
43.24 |
3,194 |
138,109 |
66,562 |
| Norwalk Leslie V | Director |
Jul 29 '26 |
Option Exercise |
139.43 |
842 |
117,400 |
2,430 |
| Norwalk Leslie V | Director |
Jul 28 '26 |
Sale |
182.01 |
1,250 |
227,508 |
1,588 |
| INGRID DELAET | Officer |
Jul 10 '26 |
Proposed Sale |
180.55 |
4,367 |
788,462 |
0 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Option Exercise |
106.02 |
4,367 |
462,989 |
20,592 |
0.62%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):